Applied Therapeutics Inc. Stock: price and insider trades · United States

Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ in the United States and focused on developing therapies for rare diseases with significant unmet medical need. Founded in January 2016 and headquartered in New York, the company has built its strategy around novel drug candidates that target validated biological pathways, with a particular emphasis on aldose reductase inhibition (ARI). As a development-stage biotech, Applied Therapeutics has no approved or commercialized drugs to date, which means the equity story is driven primarily by clinical execution, regulatory progress, and capital discipline rather than recurring product sales.([sec.gov](https://www.sec.gov/Archives/edgar/data/1697532/000095017025053840/aplt-20241231.htm?utm_source=openai))

The company’s lead program is govorestat (AT-007), an ARI candidate being advanced for classical galactosemia and other rare metabolic conditions. Applied Therapeutics also references development efforts in SORD deficiency and diabetic complications, including diabetic cardiomyopathy. This pipeline reflects a focused rare-disease strategy: rather than competing as a broad commercial pharmaceutical company, Applied Therapeutics is pursuing narrowly defined patient populations where there are few or no treatment options and where clinical differentiation can be meaningful. Its scientific positioning is based on targeting disease biology early, using biomarkers to demonstrate activity, and seeking potentially accelerated regulatory pathways where appropriate.([sec.gov](https://www.sec.gov/Archives/edgar/data/1697532/000095017025053840/aplt-20241231.htm?utm_source=openai))